TELA Bio Inc., a company specializing in soft-tissue reconstruction solutions, reported its financial results for the first quarter of 2025. The company achieved revenue of $18.5 million, marking a 12% increase compared to the same period last year and a 5% rise from the fourth quarter of 2024. This growth was driven by increased demand for their OviTex® and OviTex PRS Reinforced Tissue Matrix products, which saw revenue increases of approximately 15% and 2%, respectively, year-over-year. However, TELA Bio reported a net loss of $11.3 million for the first quarter of 2025, a significant increase from the $5.7 million net loss recorded in the same quarter of 2024. Cash and cash equivalents as of March 31, 2025, totaled $42.8 million. The company reiterated its full-year 2025 revenue guidance, projecting a range of $85.0 million to $88.0 million, which would represent a 23% to 27% growth over the full year 2024. Operating expenses for 2025 are expected to remain flat compared to 2024. A notable development in the company's operations is the full U.S. commercial launch of larger-sized OviTex PRS, aimed at simplifying complex plastic and reconstructive procedures.